 | Up a level |
Journal Article
Flamme, H., Krueger, M., Berkessel, A., Hallek, M. and Kreuzer, K. A. (2015). NOVEL NO-ASA DERIVATIVES ARE NEW PROMISING AGENTS IN THE THERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND SOLID CANCERS. Haematologica, 100. S. 418 - 419. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Flamme, H., Krueger, M., Berkessel, A., Hallek, M. and Kreuzer, K. A. (2015). Novel NO-ASA derivatives are new promising agents in the therapy of chronic lymphocytic leukemia (CLL) and solid cancers. Oncol. Res. Treat., 38. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262
Freeman, C., Dixon, M., Houghton, R., Humphrey, K., Fingerle-Rowson, G., Kreuzer, K. A., Engelke, A., Hallek, M. and Goede, V. (2015). Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset. Br. J. Haematol., 169. S. 63 - 64. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Freeman, C., Dixon, M., Houghton, R., Humphrey, K., Fingerle-Rowson, G., Kreuzer, K. A., Engelke, A., Hallek, M. and Goede, V. (2015). Risk factors associated with the development of infusion-related reactions (IRRs) in patients with chronic lymphocytic leukaemia (CLL) treated with anti-CD20 monoclonal antibodies (mAbs) in combination with chlorambucil: analysis of the prospective, randomised phase III CLL11 study dataset. Br. J. Haematol., 169. S. 63 - 64. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Azarnia, N., Petrone, M. E., Snyder, B. R., Maniar, M. and Silverman, L. R. (2015). RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). Leuk. Res., 39. S. S57 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Azarnia, N., Petrone, M. E., Snyder, B. R., Maniar, M. and Silverman, L. R. (2015). RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS). Leuk. Res., 39. S. S57 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., Dela Serna, J., Dilhuydy, M. S., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K. A., Langerak, A. W., Ritgen, M., Stilgenbauer, S., Doehner, H., Asikanius, E., Humphrey, K., Wenger, M. K. and Hallek, M. (2014). Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial. Br. J. Haematol., 165. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Jancuskova, T., Plachy, R., Stika, J., Hardekopf, D. W., Zejskova, L., Praulich, I., Kreuzer, K. A., Kosyakova, N., Liehr, T. and Pekova, S. (2014). CHARACTERIZATION OF THE RARE TRANSLOCATION T(3;10)(Q26;Q21) IN AN ACUTE MYELOID LEUKEMIA PATIENT. Haematologica, 99. S. 283 - 285. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Kleffner, F., Praulich, I, Kreuzer, K. A. and Hartmann, K. (2013). Simultaneous Occurrence of two Kit Exon 17 Mutations in a Patient with systemic Mastocytosis and severe Anaphylaxis. J. Dtsch. Dermatol. Ges., 11 (11). S. 1102 - 1103. HOBOKEN: WILEY-BLACKWELL. ISSN 1610-0387
Loeschcke, K., Fink, A., Bahlo, J., Westermann, A., Zey, A., Fischer, K., Wendtner, C. M., Noesslinger, T., Ghia, P., Bosch, F., Kater, A. P., Kreuzer, K. A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). CENTRAL SCREENING ENABLES IDENTIFICATION OF HIGH RISK CLL PATIETNS FOR LENALIDOMIDE MAINTENANCE THERAPY WITHIN THE CLLM1 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 587 - 589. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Navada, S. C., Azarnia, N. and Garcia-Manero, G. (2015). BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? Leuk. Res., 39. S. S44 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Silverman, L. R., Fenaux, P., Al-Kali, A., Baer, M. R., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D. P., Kambhampati, S., Kreuzer, K. A., Godley, L., Collins, R., Atallah, E., Navada, S. C., Azarnia, N. and Garcia-Manero, G. (2015). BONE MARROW BLAST (BMBL) RESPONSE CORRELATES WITH OVERALL SURVIVAL IN RIGOSERTIB-TREATED PATIENTS WITH HIGHER-RISK MDS AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS): A NEW RESPONSE CRITERION? Leuk. Res., 39. S. S44 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 1873-5835
Skoetz, N., Rancea, M., Trelle, S., Nueesch, E., Engert, A. and Kreuzer, K. A. (2015). COMPARISON OF TYROSINE-KINASE INHIBITORS AS FIRST-LINE TREATMENT FOR CHRONIC MYELOID LEUKEMIA: RESULTS OF A NETWORK META-ANALYSIS INCLUDING 6314 PATIENTS. Haematologica, 100. S. 433 - 434. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M. and Sharman, J. P. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 521 - 522. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078